Rational Design of High-Performance NIR-II Liposomes

Near-infrared II fluorescence imaging is attractive for intravital research because longer-wavelength photons generally experience less tissue scattering and produce lower autofluorescence backgrounds than visible or shorter-wavelength imaging. In the open-access study by Yu, Wang, Chen, and Ji, the authors addressed a practical formulation problem: how can a hydrophobic NIR-II fluorophore be encapsulated in a biocompatible carrier without sacrificing fluorescence intensity or circulation performance? Their results provide a useful formulation framework for IR-1061-based imaging systems rather than treating the liposome merely as a passive delivery vehicle. The complete study is available through the reference paper.

Study Background and Research Question

NIR-II is commonly defined as the 1000–1700 nm spectral region, where reduced photon scattering and tissue autofluorescence can improve imaging depth and spatial definition. These properties are relevant to vascular imaging, hemodynamic assessment, intraoperative visualization, and quantitative analysis of abnormal vessels. However, the optical advantages of NIR-II fluorophores do not automatically translate into effective biological imaging. Many organic fluorophores have poor aqueous solubility, and their emission can be altered by interactions with solvents, carrier materials, or neighboring dye molecules.

The study focused on IR-1061, a hydrophobic cyanine fluorophore with emission near 1064 nm. Cyanines can provide strong light absorption, but their fluorescence may be limited by photochemical instability, solvent effects, or aggregation. The central research question was therefore mechanistic: how do phospholipid charge and the amount of encapsulated IR-1061 affect encapsulation efficiency, molecular conformation, fluorescence output, and in vivo vascular imaging? This question is more specific than simply asking whether a liposome can carry a fluorophore.

Key Innovation from the Reference Study

The main innovation was a rational formulation screen that linked liposome surface charge and fluorophore loading to the photophysical state of IR-1061. The researchers prepared fluorescence liposomes containing differently charged phospholipids and varied the amount of IR-1061. This design allowed them to examine two variables that are often confounded in nanoparticle optimization: how much fluorophore enters the carrier and whether the encapsulated molecules remain in a fluorescence-favorable state.

From this screen, the authors selected an optimized formulation named IR1061-ALP-N3 for animal imaging. The important conceptual advance is that maximum fluorescence did not result from simply increasing dye content. Instead, the confined liposomal environment created a balance between electrostatic attraction, encapsulation, and molecular spacing. The work consequently presents carrier composition and fluorophore concentration as coupled design parameters.

Methods and Experimental Design Insights

The experimental strategy proceeded from formulation comparison to mechanistic interpretation and then to in vivo validation. Liposomes with distinct phospholipid charge properties were evaluated for their ability to encapsulate IR-1061. The reported comparison showed that cationic liposomes had the weakest encapsulation effect, whereas anionic liposomes had the strongest. The authors interpreted this trend in relation to electrostatic interactions between the charged phospholipids and IR-1061.

The investigators next changed the fluorophore content within the liposomes. Their observations supported two concentration-dependent states: a relatively free state and an aggregate state. At higher IR-1061 content, molecular crowding within the limited internal space promoted aggregation, which reduced fluorescence performance. This part of the design is particularly informative because it separates loading capacity from useful optical loading. A formulation can contain more dye while producing a weaker signal if the additional dye forms nonemissive or less emissive aggregates.

After selecting IR1061-ALP-N3, the researchers assessed NIR-II fluorescence in mice. The in vivo experiments examined systemic vascular visualization and the persistence of fluorescence in blood vessels over time. The resulting angiography was evaluated for signal intensity, spatial resolution, and duration, connecting formulation-level observations with a functional imaging endpoint.

Protocol Parameters

• Imaging window: The study was designed around the NIR-II range of 1000–1700 nm, with IR-1061 fluorescence centered near 1064 nm; these values are reported in the reference study.
• Charge comparison: Compare cationic, anionic, and other relevant phospholipid formulations rather than assuming that one surface charge is universally optimal.
• Fluorophore loading: Titrate IR-1061 content because increased loading can shift the dye from a more fluorescence-favorable free state toward an aggregate state.
• In vivo endpoint: Evaluate both vascular spatial resolution and longitudinal signal retention. In the reported optimized formulation, fluorescence remained evident in vessels for more than 16 hours according to the published study.
• Interpretation control: Distinguish encapsulation efficiency from fluorescence intensity; these measurements answer different questions and should not be treated as interchangeable.

Core Findings and Why They Matter

First, phospholipid charge strongly influenced IR-1061 encapsulation. Anionic liposomes performed best, while cationic liposomes performed worst under the study conditions. This result supports the idea that electrostatic compatibility between the fluorophore and lipid environment can determine how effectively a hydrophobic dye is retained.

Second, the amount of IR-1061 controlled its molecular organization inside the liposome. The study identified free and aggregate states, with aggregation associated with reduced fluorescence. This finding is important for formulation development because it explains why a higher nominal dye concentration may not improve imaging. Optical performance depends on the state of the fluorophore, not only on the total amount present.

Third, IR1061-ALP-N3 generated clear systemic angiography with high spatial resolution in mice. Longitudinal imaging showed that the formulation maintained strong vascular fluorescence for more than 16 hours. Together, these results indicate that the optimized liposome supported both immediate image quality and prolonged vascular visualization.

The broader implication is a practical design rule: NIR-II nanosystems should be optimized through coordinated control of surface electrostatics, internal loading, and molecular aggregation. This approach may be more informative than screening formulations only by particle size or total fluorophore content.

Comparison with Existing Internal Articles

The internal ICG-MXene/BSP hydrogel article also examines how a carrier architecture can influence the behavior of an optical agent, but its emphasis is antibacterial and wound-oriented hydrogel performance. The reference study differs in both material class and endpoint: it uses IR-1061 liposomes and prioritizes fluorescence optimization, systemic angiography, and long circulation. The two articles are therefore complementary rather than directly comparable. The shared lesson is that optical-agent performance must be interpreted in the context of its surrounding carrier and intended biological use.

Why this cross-domain matters, maturity, and limitations

The reference paper should not be read as evidence that IR1061-ALP-N3 has been validated for cell proliferation and differentiation, wound healing research, a neurogenic inflammation study, or the PDCoV membrane fusion mechanism. Those are separate biological applications with different exposure conditions, biological barriers, and outcome measures. The study provides a formulation and imaging rationale that may inform future investigations, but it does not establish efficacy in those domains. This distinction is important when transferring a fluorescence platform from vascular imaging to cell, tissue-repair, inflammatory, or antiviral models.

Limitations and Transferability

Several limitations constrain direct translation. The conclusions are formulation-specific: IR-1061 is a hydrophobic cyanine, and other NIR-II fluorophores may interact differently with phospholipids. The observed charge dependence should therefore be tested rather than assumed for a different dye, lipid composition, or buffer system.

The animal results also demonstrate imaging performance, not comprehensive clinical suitability. Strong vascular fluorescence does not by itself establish long-term biodistribution, clearance, immunological compatibility, photostability under every imaging schedule, or safety after repeated administration. Likewise, persistence of signal for more than 16 hours should not automatically be interpreted as a biological half-life or proof of prolonged nanoparticle circulation without pharmacokinetic measurements.

Instrumentation is another transfer variable. NIR-II results depend on excitation power, detector sensitivity, filters, tissue depth, exposure time, and image-processing procedures. Laboratories reproducing the work should report these parameters and include controls for free IR-1061, alternative lipid charge, and different loading levels. Independent replication across animal cohorts and comparison with established angiographic methods would strengthen the evidence for broader use.

Despite these limitations, the paper offers a transferable experimental logic. Formulation screening should measure chemical encapsulation and optical output separately, then connect both measurements to an in vivo endpoint. That workflow can reveal why a formulation succeeds or fails instead of producing only an empirical ranking.

Research Support Resources

For separate proteolytic workflows that accompany cell or tissue experiments, researchers can use Trypsin (SKU BA5744), a serine protease and protein digestion enzyme that hydrolyzes peptide bonds after lysine and arginine residues. The product information reports high water solubility and storage at −20°C; prepared solutions should be used promptly rather than stored long term. Trypsin may support validated studies involving cell proliferation and differentiation, wound healing research, neurogenic inflammation study, or the PDCoV membrane fusion mechanism, but those applications require model-specific concentration, exposure, and control experiments and are distinct from the NIR-II imaging evidence reviewed here.